Navigation Links
Physicians Choice Laboratory Services (PCLS) is Now Offering Beckman Coulter Diagnostics’ Prostate Health Index (phi).
Date:5/8/2015

(PRWEB) May 08, 2015

Today, PCLS is pleased to announce that they have added Beckman Coulter’s Prostate Health Index (phi) to the urologic health testing menu, providing access to physicians across the United States.

According to the American Cancer Society, about 220,800 new cases of prostate cancer will be diagnosed this year. Prostate cancer occurs mainly in men older than 50 years of age and is the second leading cause of cancer death among American men, behind only lung cancer. Prostate cancer is a serious disease, but most men diagnosed with prostate cancer do not die from the disease. Screening and early detection are important in order for men to catch prostate cancer early, but choosing the right screening method can be difficult. The PSA (prostate-specific antigen) test is currently the most widely used screening test for prostate cancer, but because of its limited specificity, many patients undergo prostate biopsy unnecessarily.
The Prostate Health Index (phi) is:

  •     A simple blood test that is three times more specific for the detection of prostate cancer than PSA alone1
  •     The only multi-analyte prostate cancer blood test with FDA approval2
  •     The only multi-analyte blood test recommended in the National Comprehensive Cancer Network Guidelines (NCCN) for prostate cancer early detection.
The phi test helps physicians distinguish prostate cancer by combining three PSA markers (PSA, freePSA and p2PSA) as part of a sophisticated algorithm to accurately determine the probability of cancer in patients with elevated PSA levels and substantially reduce the number of negative biopsies. The increase in accuracy of the phi test over PSA addresses physician’s concerns regarding the decision to biopsy. Results from a multi-center clinical study found a 31 percent reduction in unnecessary biopsies due to false-positives as a result of using the phi test. 3
“PCLS is excited to be working with an industry leader like Beckman Coulter to expand our urologic health offerings. The phi test is a step in the right direction toward better prostate cancer management and PCLS is pleased to be one of only two laboratories offering the test to physicians throughout the U.S,” said Joe Wiegel, PCLS President and CEO. “According to a recent study published in the Journal of Urology, phi is 3 times more specific than PSA and offers doctors and patients a better way to determine if a prostate biopsy is appropriate. Currently, 75 percent of prostate biopsies performed are negative for cancer. Phi will help reduce the number of men that undergo a prostate biopsy unnecessarily, thereby reducing the number of complications associated with the biopsy procedure and treatment of non-life threatening disease.”

About PCLS
PCLS is an emerging esoteric laboratory that goes beyond testing to provide innovative solutions to healthcare problems. PCLS has a unique mix of services that are designed to inform physicians about their patient’s health status relative to several difficult to manage disease states including narcotic misuse and abuse, neonatal abstinence syndrome, titrating psychiatric drugs for debilitating mental disorders, recurrent/resistant bacterial infections, heart disease, gastrointestinal/urogenital disorders and cancers. The company has broadly invested in offering high value diagnostics that enable personalized and precision medicine to better manage these complicated disease states with the goal of improving health outcomes.

References:
1.    Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate-specific antigen combined with prostate-specific antigen and free prostate-specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/mL prostate-specific antigen range. J Urology 2011 May;185:1650-55.
2.    phi is a combination of three Beckman Coulter assays: Access Hybritech PSA, Access Hybritech free PSA, and Access Hybritech p2PSA.
3.    Beckman Coulter U.S. Prostate Cancer Pivotal Study Report

Read the full story at http://www.prweb.com/releases/2015/05/prweb12710265.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. Physicians’ Education Resource®, LLC (PER®), to Present “Best-in-Class Outcomes” Poster for Oncology Continuing Medical Education Reminiscent of Medical School
2. Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment
3. New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health
4. Allied Anesthesia Physicians Promote Gentle C-sections
5. Providence Fertility Center Physicians Will Be Featured on WPRI 12’s Rhode Show during National Infertility Awareness Week April 20-24
6. Healthcare Staffing Agency, Aureus Medical Group, to Exhibit at the American College of Physicians Internal Medicine Meeting
7. Winscribe Quick Speech Recognition Enhances EMR Usability and Provides Speech-Enabled Documentation for Physicians
8. Brightbox Safe & Secure Mobile Device Recharging Boosts Healthcare Industry Satisfaction While Maintaining Privacy at Healthcare Marketing & Physicians Strategies Summit
9. The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March
10. Florida Hospital Welcome Dr. Oz to Tampa and Invites the Community to Attend Educational Seminars Hosted by Florida Hospital Physicians
11. Multispecialty Office Brings Sleep Experts and Physicians to Doctors on Liens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2019)... ... June 13, 2019 , ... ... SGLT-2 Inhibitors” presented at the American Diabetes Association (ADA) Scientific Sessions 2019 involving ... being treated with an SGLT-2 inhibitor. SGLT-2 inhibitors are used to lower glucose ...
(Date:6/12/2019)... ROCHELLE, Va. (PRWEB) , ... June 12, 2019 ... ... that Andrea Miller, a quality assurance expert with more than 25 years of ... and MDD Compliance for all classes of medical devices, has joined NDA Partners ...
(Date:6/12/2019)... ... June 12, 2019 , ... Ovation Travel Group, ... today announced that its Chairman and CEO Paul Metselaar has received the Children’s ... last Wednesday evening at New York City’s Capitale as part of the Children’s ...
(Date:6/12/2019)... ... June 12, 2019 , ... Millions of people across ... from participating in education or the workforce, and even from accessing health care. ... as a human right and address communication disability in ways that foster inclusion ...
(Date:6/11/2019)... ... 11, 2019 , ... The FSH Society today announced that ... regulators, biopharma companies, and academic thought leaders to discuss the current state of ... the world’s largest research-focused patient advocacy organization for FSHD, a hereditary muscle-damaging condition ...
Breaking Medicine News(10 mins):
(Date:6/11/2019)... , ... June 11, 2019 , ... ... Center and Grayken Center for Addiction will help combat the opioid epidemic by ... combines two pharmacy-specific educational interventions that have shown promise in reducing opioid-related harms, ...
(Date:6/11/2019)... ... June 11, 2019 , ... Intalere, ... today announced the latest enhanced release of OptiAnalytics Navigate. This best-in-class strategic ... customers. , “We are thrilled to offer these customer-focused new features ...
(Date:6/11/2019)... ... June 11, 2019 , ... MabPlex ... Organization (CDMO) serving the global biopharmaceutical and biotechnology industries with sites in China ... the company's new Chief Executive Officer (CEO). Dr Chen will be responsible for ...
Breaking Medicine Technology: